Retatrutide TRIUMPH-1 (2023) and TRIUMPH-2 (2024) TRIUMPH-1 (Jastreboff et al., NEJM 2023): 338 non-diabetic adults with obesity, 48 weeks at escalating doses: 12 mg dose: 24.2% weight loss 8 mg dose: 22.8% 4 mg dose: 17.5% Placebo: 2.1% TRIUMPH-2 (Rosenstock et al., Lancet 2024) confirmed effects in T2D patients with concurrent NAFLD improvement (hepatic fat reduction 54% at 24 weeks, 12 mg dose)
The action of a natural hormone GLP-1 is emulated by Semaglutide
If possible, keep a small thermometer in the fridge to verify the temperature stays between 36 and 46 degrees
[Google Scholar] Injectable fillers: Current status, physicochemical properties, function mechanism, and perspectives
Conventional glycemic control models prioritize the reduction of HbA1c, with a predominant focus on averting microvascular and macrovascular complications